<p>Caris Life Sciences Inc. has published a new study in Nature’s npj Breast Cancer journal detailing mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. The study, which analyzed real-world data from 2,799 T-DXd-treated patients, identified ERBB2 (HER2) and ABCC1 as key transcriptomic predictors of overall survival specific to T-DXd treatment. Higher ERBB2 expression was associated with improved outcomes, while higher ABCC1 expression correlated with poorer outcomes, independent of HER2 category. The research also found that increased ABCC1 expression and enrichment of mutations in ERBB2, NFE2L2, KEAP1, and TOP1 were present in post-treatment samples, suggesting routes to acquired resistance. The results of this study have already been published. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA72134) on January 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Reuters

iShares US Pharma

Proshares Ultra Nasdaq Biotech

iShares US Healthcare Providers

Direxion S&P Biotech Bear 3X

VG Health

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Caris Life Sciences

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

iShares Genomics Immunology and Healthcare ETF

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

iShares US Medical Devices

Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer